Physician profile
Premesh Malapati
NPI 1730136763
$1,746.50
in general payments reported to CMS, 2019-2025
27 companies · $92.28 in 2025
The $92.28 reported for 2025 was less than what a typical Internal Medicine provider received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $394 · 2020: $235 · 2021: $349 · 2022: $252 · 2023: $194 · 2024: $231 · 2025: $92.28.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $517.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $517.26 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $430.26 | 2019-2025 | Rybelsus, Ozempic, Wegovy |
| Baxter Healthcare | $220.73 | 2023-2024 | Peri-Strips Dry |
| Novartis Pharmaceuticals Corporation | $192.01 | 2019-2022 | |
| Glaxosmithkline, LLC. | $110.14 | 2019-2020 | |
| Abbvie INC. | $103.59 | 2020-2024 | |
| Janssen Pharmaceuticals, INC | $97.16 | 2019-2020 | |
| Merck Sharp & Dohme LLC | $85.61 | 2021-2022 | |
| Astellas Pharma US INC | $57.67 | 2019-2020 | |
| Lilly USA, LLC | $48.29 | 2021 | |
| Amarin Pharma, INC. | $40.33 | 2019 | |
| E.R. Squibb & Sons, L.L.C. | $34.83 | 2021 | |
| Astrazeneca Pharmaceuticals Lp | $32.23 | 2020 | |
| Pfizer INC. | $30.49 | 2023 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $29.99 | 2021-2024 | Xifaxan |
| Sunovion Pharmaceuticals INC. | $26.05 | 2019 |
Show all 27 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Xeris Pharmaceuticals, INC. | $24.80 | 2023 | Gvoke Hypopen |
| Abbott Laboratories | $23.99 | 2021 | |
| Amgen INC. | $20.02 | 2024 | Krystexxa |
| Vivus LLC | $20.00 | 2019 | |
| Mylan Specialty L.P. | $16.89 | 2024 | Yupelri |
| Exact Sciences Corporation | $16.73 | 2024 | Cologuard Collection Kit |
| Takeda Pharmaceuticals U.S.A., INC. | $15.53 | 2019 | |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $14.42 | 2022 | |
| Allergan, INC. | $13.95 | 2019 | |
| Gilead Sciences, INC. | $13.93 | 2020 | |
| Hikma Pharmaceuticals USA | $13.43 | 2021 | |
| Eyevance Pharmaceuticals LLC | $13.43 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Premesh Malapati listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.